SuperTROPO (Better Diagnostics of Myocardial Infarction With a Test for Special Forms of Troponin)

Recruiting

• Conditions: Myocardial Infarction; Myocardial Ischemia
• Interventions: Diagnostic Test: SuperTROPO novel assay to measure the long forms of cTnT

• Registration Number: NCT05858112
• Lead Sponsor: Turku University Hospital

Brief Summary

The aim of this study is to investigate whether measurement of the long forms of cTnT with the novel SuperTROPO assay would improve the diagnosis of myocardial infarction in patients in the emergency department. The main goals are:

1. To assess whether measuring long forms of cTnT with the novel SuperTROPO assay and determining the ratio of long cTnT and standard high-sensitivity cTnT could separate patients with type 1 NSTEMI patients from patients with other causes of minor (\> 14ng/L) cTnT elevation in a single admission blood sample in unselected emergency department patients with clinical indication for troponin measurement.

2. To compare the level of long cTnT and the ratio of long cTnT and standard cTnT in patients with type 1 MI and various clinical patient groups admitted to emergency department with elevated standard cTnT, e.g. patients with atrial fibrillation, heart failure or renal impairment.

3. To evaluate optimal cut-off values for long cTnT and its ratio to standard cTnT in the exclusion and diagnosis of MI in a clinical setting with elevated (\>14ng/L) cTnT.

4. To evaluate how time from symptom onset and peak symptom to blood sampling, as well as comorbidities and patients' age impact the discriminative capacity of long cTnT and cTnT ratio between patients with and without type 1 MI.

5. To investigate whether information on long cTnT and its ratio to standard cTnT can be used to cut down unnecessary coronary angiographies and hospital admissions

The long forms of cTnT are measured from the residual blood samples routinely collected from patients with suspected myocardial infarction.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2023-04-25
• Study Start: 2023-05-01
• Study First Submitted QC: 2023-05-04
• Study First Posted: 2023-05-15
• Status Verified: 2023-11
• Last Update Submitted: 2023-11-21
• Last Update Posted: 2023-11-27
• Primary Completion: 2024-11
• Study Completion: 2025-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 3000

Inclusion Criteria

• Patient has arrived at the emergency department and high-sensitivity cTnT test (P-TnT) has been ordered as part of the routine "cardiac package" of laboratory tests upon arrival
• Result of >14 ng/L of the P-TnT test included in the "cardiac package"
• Age > 18
• The patient or his/her legal representative has given written informed consent for participation in the study

Read More

Exclusion Criteria

• unable to give informed consent
• legally incompetent individuals
• pregnancy
• previously participated in this study

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Patients with suspected MI	SuperTROPO novel assay to measure the long forms of cTnT	-

Primary Outcome Measures

Name	Time	Method
Myocardial infarction type 1	During the index hospitalization, that is, the hospitalization after the drawn blood samples at the emergency department. Up to 12 weeks.	In brief, type 1 MI will be diagnosed when there is evidence of myocardial necrosis along with a clinical setting consistent with acute myocardial ischemia, as well as a coronary plaque rupture or erosion and superimposed thrombosis. The presence of the final diagnosis of type 1 MI by the treating clinician will be reviewed from patient records of the index hospitalization. Furthermore, patients with type 2 MI, will be identified and analyzed separately. The proportion of patients with type MI will be calculated and troponin values will be compared with patients with and without MI. .

Trial Locations

Locations (1)

Turku University Hospital; 🇫🇮 Turku, Finland